--- title: "\"Performance\" KING FOOK HOLD's interim net profit is HKD 39.72 million, an increase of 7.2%, with a dividend of 0.4 cents" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/266074541.md" description: "KING FOOK HOLD announced its interim results for the six months ended September, with revenue of HKD 416 million, an increase of 7.5% year-on-year. It recorded a net profit of HKD 39.72 million, a growth of 7.2%, with earnings per share of HKD 0.0437. The interim dividend remains at HKD 0.004" datetime: "2025-11-16T10:28:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/266074541.md) - [en](https://longbridge.com/en/news/266074541.md) - [zh-HK](https://longbridge.com/zh-HK/news/266074541.md) --- > 支持的语言: [English](https://longbridge.com/en/news/266074541.md) | [繁體中文](https://longbridge.com/zh-HK/news/266074541.md) # "Performance" KING FOOK HOLD's interim net profit is HKD 39.72 million, an increase of 7.2%, with a dividend of 0.4 cents KING FOOK HOLD (00280.HK) announced its interim results for the six months ended September, with revenue of HKD 416 million, an increase of 7.5% year-on-year. It recorded a net profit of HKD 39.72 million, a growth of 7.2%, with earnings per share of HKD 0.0437. The interim dividend remains at HKD 0.004 ### 相关股票 - [KING FOOK HOLD (00280.HK)](https://longbridge.com/zh-CN/quote/00280.HK.md) ## 相关资讯与研究 - [February US Retail Sales Ex Auto, Gas Rise 0.4% Vs. Expected 0.3% Gain, Prior 0.2% Gain](https://longbridge.com/zh-CN/news/281370014.md) - [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md) - [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-CN/news/281223382.md) - [Results: Flat Glass Group Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts](https://longbridge.com/zh-CN/news/280891760.md) - [UK February retail sales -0.4% vs -0.7% m/m expected](https://longbridge.com/zh-CN/news/280742189.md)